In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cigna Corp.

www.cigna.com

Latest From Cigna Corp.

Rx Pricing, Rebating Should Be Back To Business As Usual In 2020, PBMs Say

Political focus of drug pricing debate has shifted away from pharmacy benefit managers, CVS Health’s Merlo suggests.

Pricing Debate Reimbursement

Curative Gene Therapy Coverage May Need Government-Funded Risk Pools

Former US FDA commissioner Scott Gottlieb makes a case for regional or national risk pools to ensure pediatric patients get timely access to gene therapy like the upcoming treatments for sickle cell disease.

Pricing Debate Policy

Cigna/Express Scripts Gene Therapy Solution Involves Plans ‘Pre-Paying’ For Coverage

Approach designed to avoid price “shock” when coverage for Luxturna or Zolgensma is requested. Plans would agree to certain per member per month payments to enroll in the program, which would cover both plan and patient costs for gene therapy.
Gene Therapy Reimbursement

Employers Would ‘Welcome’ Government Role In Covering High-Cost Therapies

Annual large employer health benefits survey for 2020 and beyond finds support for government price negotiation and payment through a national fund. Plans to expand point-of-sale rebates and coupon accumulator programs also reported.

Reimbursement Pricing Strategies
See All

Company Information

UsernamePublicRestriction

Register